Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Automera logo — Empowering the next evolution in degradation platforms.

Automera

Empowering the next evolution in degradation platforms.

Founded 2022 Singapore Singapore 14 employees Series A Total: $16.00M Biotechnology, Health and Wellness

General Information

Company Name Automera
Founded Year 2022
Location Singapore Singapore
Employees 14
Industries Biotechnology, Health and Wellness
Funding Stage Series A
Business Model B2B, Platform
Revenue Model Licensing, Project Based, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Automera. To contact Automera, visit automeratx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Automera compare?

A PDF of Automera and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Automera soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Automera

Automera is an early-stage biotechnology company founded in 2022 in Singapore. The company's mission is to develop a groundbreaking therapeutic approach through autophagy-based targeted protein degradation. Automera sets itself apart by combining its deep understanding of autophagy with advanced drug development capabilities, as well as access to quantum chemistry and generative AI-enabled insights to drive its drug development programs. One of the key highlights of Automera is its AUTAC platform, which exhibits significant potential across a wide range of diseases, with a primary focus on oncology as its lead program. The company's commitment to leveraging cutting-edge technologies positions it as an innovative player in the biotech space. On 27 September 2023, Automera secured a notable $16.00M Series A investment from prominent backers including EDBI, Accelerator Corp., Xora Innovation, and ClavystBio. This investment reflects the confidence of industry players in Automera's potential to revolutionize targeted protein degradation and make a meaningful impact in the field of therapeutics.

Business keywords: biotech, drug development, therapeutic approach, autophagy, protein degradation, oncology, cancer, disease areas, quantum chemistry, AI-enabled insights, Talo Labs Pte Ltd, early-stage, AUTAC platform, founder-led

Services & Products

Designing chimeric small molecules
Developing precision-targeted therapies
Enhancing drug development processes

Target Customers

Pharmaceutical companies Biotech researchers Healthcare organizations focused on difficult-to-treat diseases

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $16.00M 4
EDBI Accelerator Corp. Xora Innovation
EDBI, Accelerator Corp. +2
27 Sep 2023

Automera Alternatives & Competitors

View All Alternatives
Automera vs
Monte Rosa Therapeutics
Monte Rosa Therapeutics United States

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecu...

IPO
230 employees
Biotechnology, Health and Wellness
Automera vs
Relay Therapeutics
Relay Therapeutics United States

Integrating leading-edge computational and experimental science to transform human health.

IPO
230 employees
Biotechnology, Health Care
Automera vs
Laronde
Laronde United States

Pioneering a completely novel translatable RNA platform - Endless RNA (eRNA)

Series B
44 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Automera

Empowering the next evolution in degradation platforms.
Automera was founded in 2022.
Automera is headquartered in Singapore.
Automera operates in Biotechnology and Health and Wellness. Its work centres on biotech, drug development, therapeutic approach and autophagy. Its customers include Pharmaceutical companies, Biotech researchers and Healthcare organizations focused on difficult-to-treat diseases.
Automera has a B2B and Platform business model. Its revenue comes from Licensing, Project Based and Performance Based.
Automera has approximately 14 employees.
Automera has completed 1 funding round, raising a total of $16.00M. The latest funding stage is Series A.
Automera offers: Designing chimeric small molecules, Developing precision-targeted therapies, Enhancing drug development processes.
Top alternatives and competitors to Automera include Monte Rosa Therapeutics, Relay Therapeutics, Laronde, Oncorena AB, Montara Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Automera and Monte Rosa Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Automera, https://bouncewatch.com/company/automera, updated 29 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout